Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Raw Materials (2018 - 2025)

TransMedics has reported Raw Materials over the past 8 years, most recently at $26.2 million for Q4 2025.

  • Quarterly results put Raw Materials at $26.2 million for Q4 2025, down 6.34% from a year ago — trailing twelve months through Dec 2025 was $26.2 million (down 6.34% YoY), and the annual figure for FY2025 was $26.2 million, down 6.34%.
  • Raw Materials for Q4 2025 was $26.2 million at TransMedics, up from $20.3 million in the prior quarter.
  • Over the last five years, Raw Materials for TMDX hit a ceiling of $28.0 million in Q3 2024 and a floor of $6.1 million in Q1 2021.
  • Median Raw Materials over the past 5 years was $17.0 million (2023), compared with a mean of $16.8 million.
  • Biggest five-year swings in Raw Materials: soared 136.06% in 2023 and later plummeted 30.35% in 2025.
  • TransMedics' Raw Materials stood at $7.3 million in 2021, then surged by 50.38% to $10.9 million in 2022, then soared by 136.06% to $25.8 million in 2023, then grew by 8.54% to $28.0 million in 2024, then fell by 6.34% to $26.2 million in 2025.
  • The last three reported values for Raw Materials were $26.2 million (Q4 2025), $20.3 million (Q3 2025), and $19.2 million (Q2 2025) per Business Quant data.